These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 1831370)

  • 1. [Progression of functional disability in 70 patients with multiple sclerosis].
    Izquierdo G; Quesada MA; Navarro G; Aguilar J; Rodríguez Moreno E; Girón JM; Martínez-Parra C
    Neurologia; 1991 May; 6(5):170-4. PubMed ID: 1831370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural history of multiple sclerosis: a unifying concept.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disability progression in multiple sclerosis is slower than previously reported.
    Tremlett H; Paty D; Devonshire V
    Neurology; 2006 Jan; 66(2):172-7. PubMed ID: 16434648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies.
    Ozakbas S; Ormeci B; Idiman E
    J Neurol Sci; 2005 May; 232(1-2):65-9. PubMed ID: 15850584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Late onset multiple sclerosis].
    Delalande S; De Seze J; Ferriby D; Stojkovic T; Vermersch P
    Rev Neurol (Paris); 2002 Nov; 158(11):1082-7. PubMed ID: 12451340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is late-onset multiple sclerosis associated with a worse outcome?
    Tremlett H; Devonshire V
    Neurology; 2006 Sep; 67(6):954-9. PubMed ID: 17000960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease.
    Kremenchutzky M; Rice GP; Baskerville J; Wingerchuk DM; Ebers GC
    Brain; 2006 Mar; 129(Pt 3):584-94. PubMed ID: 16401620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age at disability milestones in multiple sclerosis.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):595-605. PubMed ID: 16415309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The natural history of primary progressive multiple sclerosis.
    Koch M; Kingwell E; Rieckmann P; Tremlett H
    Neurology; 2009 Dec; 73(23):1996-2002. PubMed ID: 19996074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A clinical longitudinal study of multiple sclerosis in Cantabria, Spain.
    Morís G; Berciano J; Miró J
    Neurologia; 2003 Dec; 18(10):723-30. PubMed ID: 14648348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical course of multiple sclerosis patients in Hong Kong.
    Lau KK; Wong WW; Sheng B; Yu IT; Fung BH; Li HL; Ma KF; Wong LK; Li PC
    J Neurol Sci; 2008 May; 268(1-2):78-82. PubMed ID: 18068191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the natural history and prognostic features of early onset and adult onset multiple sclerosis in Jordanian population.
    El-Salem K; Khader Y
    Clin Neurol Neurosurg; 2007 Jan; 109(1):32-7. PubMed ID: 16870328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics of multiple sclerosis in Lebanon.
    Yamout B; Barada W; Tohme RA; Mehio-Sibai A; Khalifeh R; El-Hajj T
    J Neurol Sci; 2008 Jul; 270(1-2):88-93. PubMed ID: 18367208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Primary progressive forms of multiple sclerosis: application of the new diagnostic criteria in French].
    De Seze J; Mackowiak A; Stojkovic T; Ferriby D; Hautecoeur P; Vermersch P
    Rev Neurol (Paris); 2002 Mar; 158(3):341-5. PubMed ID: 11976594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective clinical and electrophysiological follow-up on a multiple sclerosis population treated with interferon beta-1 a: a pilot study.
    Feuillet L; Pelletier J; Suchet L; Rico A; Ali Cherif A; Pouget J; Attarian S
    Mult Scler; 2007 Apr; 13(3):348-56. PubMed ID: 17439904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The natural history of multiple sclerosis with childhood onset.
    Renoux C; Vukusic S; Confavreux C
    Clin Neurol Neurosurg; 2008 Nov; 110(9):897-904. PubMed ID: 18534742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age at onset determines the occurrence of the progressive phase of multiple sclerosis.
    Stankoff B; Mrejen S; Tourbah A; Fontaine B; Lyon-Caen O; Lubetzki C; Rosenheim M
    Neurology; 2007 Mar; 68(10):779-81. PubMed ID: 17339588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain atrophy evolution and lesion load accrual in multiple sclerosis: a 2-year follow-up study.
    Tedeschi G; Dinacci D; Comerci M; Lavorgna L; Savettieri G; Quattrone A; Livrea P; Patti F; Morra VB; Servillo G; Orefice G; Paciello M; Prinster A; Coniglio G; Bonavita S; Di Costanzo A; Bellacosa A; Valentino P; Quarantelli M; Brunetti A; Salemi G; D'Amelio M; Simone I; Salvatore M; Bonavita V; Alfano B
    Mult Scler; 2009 Feb; 15(2):204-11. PubMed ID: 18987104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypothalamo-pituitary-adrenal axis activity predicts disease progression in multiple sclerosis.
    Gold SM; Raji A; Huitinga I; Wiedemann K; Schulz KH; Heesen C
    J Neuroimmunol; 2005 Aug; 165(1-2):186-91. PubMed ID: 15935481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.